Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Leidos Holdings has drawn a convergence of negative signals this week. A JP Morgan downgrade, elevated options put demand, and a sharp rise in borrowing costs are all pointing in the same direction ahead of the November 3 earnings print.
JP Morgan's Seth Seifman cut LDOS from Overweight to Neutral on October 8, slashing his target 11% to $142 from $160. That move carried weight. JP Morgan had been one of the more constructive voices on the stock. The cut brought it into line with a Wall Street consensus that has been drifting steadily lower since August.
The broader target-cutting trend is now well-established. Since this article's predecessor on October 7, Citigroup maintained its Buy but cut from $161 to $141. Jefferies and TD Cowen both trimmed Hold targets to $130. The consensus mean now sits at $151.73, against a close of $121.68. That gap looks wide. The direction of travel is what matters: every significant revision over the past two months has been a cut, not a raise.
The bear case, as Leidos management itself has flagged, centres on a 0.8x book-to-bill ratio, Health segment normalization, and ongoing federal budget uncertainty. These are not new concerns, but the JP Morgan move signals the bull camp is shrinking.
Options traders were ahead of the analyst community. The put-call ratio hit 0.595 on October 8, two standard deviations above its 20-day mean of 0.497, as the stock was sliding 15% over the prior month. That put demand has since eased slightly, with the PCR at 0.465 as of October 9, now modestly below its 20-day mean.
Cost to borrow jumped 84% over the past week to 0.46%. In absolute terms that remains low. Availability is extremely wide at 4,386%, meaning roughly 44 shares are available to borrow for every one already lent out. The lending market is not tight. The CTB move likely reflects increased demand for hedges around the earnings date rather than any structural squeeze dynamic.
The November 3 print is now the focal point. The bull case, per Benzinga's framing, rests on the Entrust acquisition lifting 2026 guidance and strong defense tech award momentum. The bear case is a softer second half and Health margin pressure. With targets still falling and options traders recently positioning for further downside, the earnings result will need to clear a bar that is simultaneously lower on paper and higher in sentiment terms.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
